Abstract
Diabetes mellitus is causing dysfunction of the vascular endothelial cells, which results in various pathologies within the microvascular and macrovascular system including retinopathy, neuropathy, nephropathy, and angiopathy. Endothelial dysfunction is caused by hyperglycemia via different mechanisms, such as damage to the glycocalyx, activation of the inflammation, oxidative stress, stimulation of cellular senescence, induction of imbalance between coagulation and fibrinolysis. Many studies suggests that inhibition of retinal endothelial dysfunction may be an effective way of slowing the progress of diabetic retinopathy. Sulodexide (glycosaminoglycans composed from heparin-like and dermatan fractions)is associated with a protective and regenerating action on the glycocalyx, slows down senescence of human venous and arterial endothelial cells. Moreover its mechanism of action involves an anti-inflammatory, anti-proteolytic, and antioxidant effect, including interference with metabolic and non-metabolic stress. In present study sulodexide was chosen to evaluate its therapeutic properties for the treatment of diabetic retinopathy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
